Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 115,640 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Daniel Patrick O’day also recently made the following trade(s):

• On Wednesday, January 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00.
• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.

Gilead Sciences Price Performance

Shares of GILD stock traded up $3.13 during midday trading on Friday, reaching $152.50. 8,509,218 shares of the company traded hands, compared to its average volume of 7,754,722. The firm’s 50 day simple moving average is $126.84 and its two-hundred day simple moving average is $120.60. The firm has a market cap of $189.20 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $153.13.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Finally, Leerink Partners upped their price objective on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $136.73.

Institutional Trading of Gilead Sciences

Several institutional investors have recently made changes to their positions in GILD. Paulson Wealth Management Inc. increased its stake in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 67 shares during the last quarter. Alpha Cubed Investments LLC increased its position in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC grew its stake in Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the period. Moss Adams Wealth Advisors LLC increased its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares in the last quarter. Finally, Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 12.5% in the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 79 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.